This excerpt taken from the CRGN 8-K filed Oct 26, 2006.
- Conference call today at 11:00 a.m. Eastern time -
BRANFORD, Conn. October 26, 2006 CuraGen Corporation (NASDAQ: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) today provided an update on the intravenous PXD101 clinical development program and reported preliminary results from three clinical trials. Preliminary results include data from a Phase Ib/II trial of PXD101 in combination with paclitaxel and carboplatin for advanced solid tumors, a Phase II trial of PXD101 monotherapy and in combination with dexamethasone for advanced multiple myeloma (MM) and a Phase Ib/II trial of PXD101 in combination with 5-fluorouracil for advanced solid tumors.
The emerging clinical results from our PXD101 clinical development program are very encouraging. We believe these results, along with data being generated by the NCI-sponsored trials, will enable us to define the most efficient path toward registration, commented Dr. Timothy Shannon, Executive Vice President of R&D and Chief Medical Officer. The level of activity noted with PXD101, in combination with commonly used chemotherapy agents for patients with advanced cancers, highlights the competitiveness of our HDAC development program. We look forward to presenting clinical data in a peer-reviewed fashion at medical conferences later this year and throughout 2007. Based on these and additional data from the PXD101 development program, we expect to make decisions in 2007 regarding which indications will be advanced into registrational development during 2008.